Tax treatment of ordinary share dividend for shareholders on the South African register
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
South African income tax number: 9950122714
(“Mediclinic”, the “Company” or the “Group”)
20 June 2019
TAX TREATMENT OF ORDINARY SHARE DIVIDEND FOR SHAREHOLDERS ON THE SOUTH AFRICAN REGISTER
Shareholders on the South African register of the Company are referred to Mediclinic’s
announcement of the results for the year ended 31 March 2019 and proposed dividend
announcement released on the Stock Exchange News Service and on the Regulatory News
Service on 23 May 2019, confirming that the Board of Directors of Mediclinic had proposed a
final dividend from retained earnings of 4.70 pence per ordinary share for the year ended
31 March 2019 for approval by the Company’s shareholders at the annual general meeting on
Wednesday, 24 July 2019.
The final dividend will be paid on Monday, 29 July 2019 to all ordinary shareholders who are
on the register of members at the close of business on the record date of Friday, 14 June 2019.
Shareholders on the South African register will be paid the ZAR cash equivalent of 86.24500
cents (68.99600 cents net of dividend withholding tax) per share. A dividend withholding tax of
20% will be applicable to all shareholders on the South African register who are not exempt
therefrom. The ZAR cash equivalent has been calculated using the following exchange rate:
GBP1: ZAR18.35, being the 5-day average GBP/ZAR exchange rate (Bloomberg) on Friday,
17 May 2019 at 3:00pm GMT.
Tax treatment for shareholders on the South African register
South African tax resident shareholders on the South African register:
In terms of the Company’s Dividend Access Trust structure, eligible South African tax resident
shareholders on the South African register set out below will receive a component of the
dividend, namely 85.21178 cents per share, from the Dividend Access Trust and therefore
regarded as a local South African dividend, with the remaining component, namely 1.03322
cents per share, being received from the Company and therefore regarded as a foreign non-
South African dividend. For purposes of South African dividend withholding tax, the entire
dividend of 86.24500 cents per share is taxable at a rate of 20%, unless an applicable
1. in the case of shares held in certificated form, eligible shareholders who are registered
on the South African register with an address in South Africa (other than PLC Nominees
Proprietary Limited (or any successor entity through which shares held in dematerialised
form are held); and
2. in the case of shares held in dematerialised form, in respect of whom the South African
transfer secretaries of the Company have determined, in good faith and by reference to
the information provided to them by the eligible shareholders and/or their brokers and/or
central securities depository participants, that such eligible shareholders are either (i) tax
resident in South Africa or (ii) have an address in South Africa and have not expressly
indicated that they are not tax resident in South Africa as at the dividend record date.
Non-South African tax resident shareholders on the South African register:
Non-South African tax resident shareholders on the South African register will be paid the
dividend by the Company in the usual way and not through the Dividend Access Trust. The
entire dividend of 86.24500 cents per share payable to such shareholders will therefore be
regarded as a foreign dividend and exempt from South African dividend withholding tax,
provided that the relevant exemption forms have been completed and submitted as prescribed.
About Mediclinic International plc
Mediclinic is an international private healthcare services group, established in South Africa in
1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the
United Arab Emirates.
The Group’s core purpose is to enhance the quality of life.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the
continuum of care in such a way that the Group will be regarded as the most respected and
trusted provider of healthcare services by patients, medical practitioners, funders and
regulators of healthcare in each of its markets.
Mediclinic comprises 77 hospitals, five sub-acute hospitals, 12 day case clinics and 21
outpatient clinics. Hirslanden operates 18 hospitals, two day case clinics and three outpatient
clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa
operates 52 hospitals, five sub-acute hospitals and 12 day case clinics with more than 8 500
inpatient beds; and Mediclinic Middle East operates seven hospitals, two day case clinics and
21 outpatient clinics with more than 900 inpatient beds in the United Arab Emirates.
The Company’s primary listing is on the London Stock Exchange (‘LSE’) in the United
Kingdom, with secondary listings on the Johannesburg Stock Exchange in South Africa and
the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private
healthcare group based in the United Kingdom and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569
James Arnold, Head of Investor Relations, Mediclinic International plc
+44 (0)20 3786 8181
Deborah Scott/Brett Pollard – United Kingdom
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
Date: 20/06/2019 03:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Email this JSE Sens Item to a Friend.